ATLAS ANTIBODIES

PAN-CANCER MARKERS FOR PROTEOMIC PHENOTYPING

Shared Signatures Across Diverse Cancer Types

Pan-cancer markers refer to molecular characteristics, genetic mutations, altered gene expression patterns, or other molecular features consistently observed and shared across a spectrum of cancers.



Genomic studies play a crucial role in identifying DNA alterations, such as mutations, copy number variations, and structural rearrangements, that contribute to the initiation and progression of various cancers.

Transcriptomic analyses, which examine the expression patterns of genes, provide insights into the functional activity of genes and molecular pathways.

Proteomic investigations focus on the study of proteins, reflecting the functional outcomes of genomic and transcriptomic changes.

Insights into **cancer mechanisms** by the integration of a multi -omics approach enhances our understanding of human cancers and provide a comprehensive view of the molecular landscape of pan-cancer markers.

Pan-cancer markers contribute to the development of **universal diagnostic strategies**, allowing for the identification of common genetic mutations across diverse cancers.

Precision medicine advancements aim to **tailor treatments** based on individual genomic and proteomic profiles.

In the rapidly evolving landscape of precision medicine, the identification of pan-cancer markers represents a pivotal breakthrough in tailoring therapeutic interventions to individual patients and offer valuable insights into common pathways, potential therapeutic targets, and diagnostic strategies.

TCGA: THE CANCER GENOME ATLAS

33
CANCER TYPES ANALYZED FOR THE GENOMIC DATASET

11,000
DATA COLLECTED & ANALYSED FROM CANCER PATIENTS

>300K
CANCER PATIENTS' GENOMIC DATA SEQUENCED

>1000
GENES IDENTIFIED AS COMMONLY MUTATED ACROSS VARIOUS CANCERS.

2,5 MIL
GENETIC MUTATIONS (DNA, RNA, PROTEINS)

20-25K
PROTEINS IN THE HUMAN PROTEOME

PROTEOME SIGNIFICANCE IN CANCER STUDIES:

While genetic information reveals cellular blueprints, the dynamic realm of proteins takes center stage, dictating the intricate landscape of cancer.

ABUNDANCE AND LOCALIZATION MATTER:

Proteomics goes beyond identifying proteins, focusing on their abundance, localization, and interactions—a vital mix for deciphering cancer biology.

PROTEOMICS DRIVES TARGETED THERAPIES:

Understanding the dynamic world of proteins moves us towards targeted therapeutic interventions, marking a pivotal advancement in the era of precision medicine.

TOOLKIT: PAN-CANCER MARKERS PANEL

AKT1, CD34, EGFR, ENG, EPAS1, GAPDH, HIF1A, IDH1, MMP9, NOTCH, VEGFA, VWF	ANGIOGENESIS
AKT1, ANXA1, BAD, BAX, BCL2, BID, BIRC5, CASP8-9, FAS, MTOR, PARP1, PDCD1, PIK3CA	APOPTOSIS
KRT20, KRT7 MMP9, VIM	METASTASIS
GAPDH, HIF1A, IDH1	METABOLIC REPROGRAMMIC
AURK A-B, CCNB1, CCND1, CDK2-4-5, CDKN1A-2A, CHEK1-2, E2F1, PARP1, PLK1, TP53	CELL CYCLE
ABL1, BRAF, CSF1R, EGFR, ERBB3, ESR1, JUN, KIT, MKI67, PCNA, PGR, PTEN, SMAD2-4, VEGFA	PROLIFERATION

15% EXCLUSIVE DISCOUNT CAMPAIGN

We're excited to announce a 15% discount on our pan-cancer markers panel.

This special offer is available until August 31st, providing you with an excellent opportunity to enhance your proteomic phenotyping studies of human cancers at a reduced cost.

ATLAS ANTIBODIES
ATLASANTIBODIES.COM